Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (1-10 of 440) with videos related to

Pageof 44
Sort By:
Medical Oncology (Northwood, London, England)|December 17, 2009
Future directions in immunomodulatory therapySagar Lonial
Oncology (Williston Park, N.Y.)|December 13, 2006
Management of toxicities associated with bortezomibSagar Lonial,
Cancer Treatment Reviews|May 18, 2010
Presentation and risk stratification--improving prognosis for patients with multiple myelomaSagar Lonial
Mayo Clinic Proceedings|March 14, 2007
Designing risk-adapted therapy for multiple myeloma: the Mayo perspectiveSagar Lonial
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
Monoclonal antibodies in multiple myeloma: data from the 2015 ASH meetingSagar Lonial
Supportive Cancer Therapy|July 17, 2008
Hematopoietic cytokines: when treating the symptoms does not treat the diseaseSagar Lonial
Supportive Cancer Therapy|July 17, 2008
Immunomodulation: the role of hematopoietic cytokinesSagar Lonial
Clinical Lymphoma & Myeloma|November 1, 2008
Practical considerations for multiple myeloma: an overview of recent data and current optionsSagar Lonial
Clinical Lymphoma & Myeloma|March 8, 2008
Multiple myeloma: novel approaches for relapsed diseaseSagar Lonial
Current Hematologic Malignancy Reports|February 18, 2011
Is subcutaneous bortezomib ready for prime time?Sagar Lonial
Pageof 44

Showing results (1-10 of 440) with videos related to

Sort By:
Pageof 44
Medical Oncology (Northwood, London, England)|December 17, 2009
Future directions in immunomodulatory therapySagar Lonial
Oncology (Williston Park, N.Y.)|December 13, 2006
Management of toxicities associated with bortezomibSagar Lonial,
Cancer Treatment Reviews|May 18, 2010
Presentation and risk stratification--improving prognosis for patients with multiple myelomaSagar Lonial
Mayo Clinic Proceedings|March 14, 2007
Designing risk-adapted therapy for multiple myeloma: the Mayo perspectiveSagar Lonial
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
Monoclonal antibodies in multiple myeloma: data from the 2015 ASH meetingSagar Lonial
Supportive Cancer Therapy|July 17, 2008
Hematopoietic cytokines: when treating the symptoms does not treat the diseaseSagar Lonial
Supportive Cancer Therapy|July 17, 2008
Immunomodulation: the role of hematopoietic cytokinesSagar Lonial
Clinical Lymphoma & Myeloma|November 1, 2008
Practical considerations for multiple myeloma: an overview of recent data and current optionsSagar Lonial
Clinical Lymphoma & Myeloma|March 8, 2008
Multiple myeloma: novel approaches for relapsed diseaseSagar Lonial
Current Hematologic Malignancy Reports|February 18, 2011
Is subcutaneous bortezomib ready for prime time?Sagar Lonial
Pageof 44